# Local Coverage Determination (LCD):
### Micro-Invasive Glaucoma Surgery (MIGS) (L37244)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

<table>
<thead>
<tr>
<th>Contractor Name</th>
<th>Contract Type</th>
<th>Contract Number</th>
<th>Jurisdiction State(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06101 - MAC A</td>
<td>J - 06</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06102 - MAC B</td>
<td>J - 06</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06201 - MAC A</td>
<td>J - 06</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06202 - MAC B</td>
<td>J - 06</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06301 - MAC A</td>
<td>J - 06</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06302 - MAC B</td>
<td>J - 06</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13101 - MAC A</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13102 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13202 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13282 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14111 - MAC A</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14112 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14211 - MAC A</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14212 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14311 - MAC A</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14312 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14411 - MAC A</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14412 - MAC B</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14511 - MAC A</td>
<td>J - K</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14512 - MAC B</td>
<td>J - K</td>
</tr>
</tbody>
</table>

## LCD Information

### Document Information

<table>
<thead>
<tr>
<th>LCD ID</th>
<th>Original Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Printed on 12/12/2017. Page 1 of 11
Micro-Invasive Glaucoma Surgery (MIGS)

For services performed on or after 12/01/2017

Revision Effective Date
N/A

Revision Ending Date
N/A

Retirement Date
N/A

Source Proposed LCD
DL37244

Notice Period Start Date
10/16/2017

Notice Period End Date
11/30/2017

CMS National Coverage Policy
Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the LCD Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Section 1862(a)(1)(D) refers to limitations on items or devices that are investigational or experimental.

Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

CMS Publications:

CMS Publication 100-02, Medicare Benefit Policy Manual, Chapter 14,
10 Coverage of Medical Devices

CMS Publication 100-04, *Medicare Claims Processing Manual*, Chapter 23,

30 Services paid under the Medicare Physicians Fee Schedule

CMS Publication 100-08, *Medicare Program Integrity Manual*, Chapter 13,

5.1 Reasonable and necessary provisions in LCDs

7.1 Evidence supporting LCDs.

Coverage Guidance

**Coverage Indications, Limitations, and/or Medical Necessity**

This LCD addresses use of a group of new surgical procedures for glaucoma referred to as micro-invasive glaucoma surgery (MIGS). NGS considers one iStent or CyPass device per eye medically reasonable and necessary for the treatment of adults with mild or moderate open-angle glaucoma and a cataract when the individual is currently being treated with an ocular hypotensive medication and the procedure is being performed in conjunction with cataract surgery. The XEN device is not considered medically reasonable and necessary.

**Summary of Evidence**

Primary open-angle glaucoma (POAG) has a prevalence in the US of 2% of adults over 40 years old, or about 2.2 million people, and is expected to increase to 3.3 million in 2020 as the population ages (1). POAG is a chronic, progressive optic neuropathy in adults in which there is a characteristic acquired atrophy of the optic nerve and loss of retinal ganglion cells and their axons. It is associated with an increased intraocular pressure (IOP), due to a buildup of aqueous fluid within the eye which can lead to visual field loss and optic nerve damage, usually without any associated pain or discomfort. The increased IOP is secondary to an imbalance between aqueous fluid secretion and fluid outflow despite an open angle. Nearly 40% of those with otherwise characteristic POAG may not have elevated IOP measurements (1).

In the primary (conventional) outflow pathway from the eye, aqueous humor passes through the trabecular meshwork, enters a space lined with endothelial cells (Schlemm canal), drains into collector channels, and then into the aqueous veins. Increases in resistance in the trabecular meshwork or the inner wall of the Schlemm canal can disrupt the balance of aqueous humor inflow and outflow, resulting in an increase in IOP and glaucoma risk.

The goal in POAG is to reduce the IOP to slow the development of optic nerve damage. The IOP can be reduced by medical treatment or surgery, alone or in combination. IOP above 21 mmHg has been shown to increase rates of visual field loss. However, because of the differences in susceptibility to pressure-related disc damage among POAG patients, pressure-lowering treatments are aimed at achieving a lower “target” pressure individualized to each patient’s baseline IOP in which glaucomatous damage occurred.

When the maximum tolerated medical therapy fails to control progression of glaucomatous optic neuropathy, surgical care is considered the next treatment option. Traditional filtration surgery includes trabeculectomy (including ExPress shunt) and aqueous drainage implants (Ahmed, Baerveldt, Molteno). Trabeculectomy uses the patient’s own sclera to create a fistula to the subconjunctival space over the sclera superiorly. Aqueous drainage implants use silicone/plastic tubing and large plates to shunt aqueous to the subconjunctival space in the equatorial region of the eyeball.

While IOP outcomes are generally worse with aqueous drainage implants compared with trabeculectomy, complications such as hypotony (low pressure), and postoperative infection are reduced. However, failure rates are similar (approximately 10% of devices fail annually), and shunts still have complications, including corneal endothelial failure and erosion of the overlying conjunctiva.

The term micro-invasive or minimally invasive glaucoma surgery (MIGS) refers to a group of newer surgical...
procedures that are performed by using an ab interno (from inside the eye) approach via gonioscopic guidance and involve minimal trauma to ocular tissues. In contrast to external filtration surgeries such as trabeculectomy and aqueous tube shunt, these procedures are categorized as internal filtration surgeries. Compared with traditional filtration surgery, MIGS holds the promise of faster recovery time and less severe complications.

It is this potentially improved safety profile that opened up the indications for MIGS to include patients with early-stage glaucoma to reduce the burden of medications and problems with compliance (due to eye drop application difficulty, cost, cosmetic effects, and frequency). Another area of investigation is patients with glaucoma who require cataract surgery. An advantage of ab interno shunts is that they may be inserted into the same incision and at the same time as cataract surgery. In addition, most devices do not preclude subsequent trabeculectomy if needed. Therefore, health outcomes of interest are the IOP achieved, reduction in medication use, ability to convert to trabeculectomy, complications, and device durability.

There are three FDA approved/cleared micro-invasive surgical stents, the iStent Trabecular Micro-Bypass Stent (2011), the CyPass Micro-Stent System (July, 2016), and the XEN Glaucoma Treatment System (Nov, 2016). The iStent is a small (1 mm x 0.5 mm) L-shaped titanium device that is inserted into Schlemm’s canal to augment the natural outflow system. CyPass is a 6.35 mm long fenestrated microstent made of biocompatible polyimide inserted into the supraciliary space, thus using an alternative outflow system. The XEN45 is a 6 mm long porcine-derived gelatin stent inserted into the subconjunctival space, bypassing the natural outflow system.

Both iStent and CyPass were FDA approved for use in combination with cataract surgery to reduce IOP in adults with mild or moderate OAG and a cataract that are currently being treated with medication to reduce IOP. XEN45 was granted FDA clearance for the management of refractory glaucoma, including cases where previous surgical treatment has failed, cases of primary open angle glaucoma, and pseudoxfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. The published pivotal trial data for each, constituting the main evidentiary support, is summarized in the table below.

Published pivotal trials for FDA Approved Micro-Invasive Glaucoma Surgery*
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Journal</th>
<th>FDA</th>
<th>Study Design</th>
<th>No. of Eyes</th>
<th>Follow-up (yrs)</th>
<th>IOP ≤ 21mm Hg no Meds</th>
<th>IOP 20% no meds</th>
<th>Mean # meds</th>
<th>Mean IOP reduction (mm Hg)</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuelson, iStent Study Group (2)</td>
<td>2011</td>
<td>Ophthalmology</td>
<td>PMA</td>
<td>RCT</td>
<td>111/122</td>
<td>1 yr. (233)</td>
<td>72%/50% (p&gt;0.001)</td>
<td>66%/48% (p=0.003)</td>
<td>0.2/0.4 (p=0.011)</td>
<td>8.4/8.2 (p=NS)</td>
<td>Pressure reduction on fewer medication was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.</td>
</tr>
<tr>
<td>Craven, iStent Study Group 2 yr. follow-up (3)</td>
<td>2012</td>
<td>J Cataract Refract Surg</td>
<td>PMA</td>
<td>RCT</td>
<td>98/101</td>
<td>2 yr. (199)</td>
<td>61%/50% (p=0.036)</td>
<td>53%/44% (p=0.09)</td>
<td>0.3/0.5 (p=NS)</td>
<td>8.4/7.5 (p=NS)</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Journal</td>
<td>FDA</td>
<td>Study Design</td>
<td>No. of Eyes</td>
<td>Follow-up (yrs)</td>
<td>IOP ≤ 21mm Hg no Meds</td>
<td>IOP 20% no meds</td>
<td>Mean # meds</td>
<td>Mean IOP reduction (mm Hg)</td>
<td>Conclusions</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>---------</td>
<td>-----</td>
<td>-------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------------------</td>
<td>----------------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Vold, COMPASS Cypass Study Group (4)</td>
<td>2016</td>
<td>Ophthalmology</td>
<td>PMA</td>
<td>RCT</td>
<td>374/131</td>
<td>2yr. (480)</td>
<td>-</td>
<td>77%/60% (p=0.001)</td>
<td>0.2/0.6 (p&lt;0.001)</td>
<td>7.4/5.3 (p&lt;0.001)</td>
<td>This RCT demonstrated safe and sustained 2-year reduction in IOP and glaucoma medication.</td>
</tr>
</tbody>
</table>

Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone. Both groups had a similar favorable long-term safety profile.
*all results are depicted in the format (study group/control group)

**Analysis of Evidence**  
(Rationale for Determination)

According to the 2015 AAO POAG Preferred Practice Pattern (PPP), the “potential benefits of a combined procedure (cataract extraction with IOL implantation and glaucoma surgery) are protection against the IOP rise that may complicate cataract surgery alone, the possibility of achieving long-term glaucoma control with a single operation, and elimination of the risk of bleb failure with subsequent cataract surgery when glaucoma surgery is performed first. Therefore, an ophthalmologist may reasonably choose to perform a combined surgery because of these perceived advantages to an individual patient (1).”

In summary, NGS considers one iStent or CyPass device per eye medically reasonable and necessary for the treatment of adults with mild or moderate open-angle glaucoma and a cataract when the individual is currently being treated with an ocular hypotensive medication and the procedure is being performed in conjunction with cataract surgery. In that setting these procedures offer a reduction in IOP, decreased dependence on glaucoma medications, and an excellent safety profile. However, their role within the glaucoma treatment algorithm continues to be clarified and differs from the role of more invasive, external filtration glaucoma surgeries such as trabeculectomy or external aqueous drainage implants. Therefore, all other indications are considered not reasonable and necessary at this time.

There is insufficient evidence in the peer-reviewed literature on the safety and efficacy of the XEN device to consider it medically reasonable and necessary (see Comment Response).

---

**Coding Information**

**Bill Type Codes:**

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

011x Hospital Inpatient (Including Medicare Part A)  
012x Hospital Inpatient (Medicare Part B only)  
013x Hospital Outpatient  
014x Hospital - Laboratory Services Provided to Non-patients  
018x Hospital - Swing Beds  
021x Skilled Nursing - Inpatient (Including Medicare Part A)  
022x Skilled Nursing - Inpatient (Medicare Part B only)  
023x Skilled Nursing - Outpatient

**Revenue Codes:**

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

CPT/HCPCS Codes

**Group 1 Paragraph:**
The CPT codes in Group 1 are considered medically necessary when the Indications of Coverage are met.
Group 1 Codes:

0191T INSERTION OF ANTERIOR SEGMENT AQUEOUS DRAINAGE DEVICE, WITHOUT EXTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE TRABECULAR MESHWORK; INITIAL INSERTION

0474T INSERTION OF ANTERIOR SEGMENT AQUEOUS DRAINAGE DEVICE, WITH CREATION OF INTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE SUPRACILIARY SPACE

Group 2 Paragraph:

The CPT codes in Group 2 are considered not medically necessary.

Group 2 Codes:

0376T INSERTION OF ANTERIOR SEGMENT AQUEOUS DRAINAGE DEVICE, WITHOUT EXTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE TRABECULAR MESHWORK; EACH ADDITIONAL DEVICE INSERTION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

0449T INSERTION OF AQUEOUS DRAINAGE DEVICE, WITHOUT EXTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE SUBCONJUNCTIVAL SPACE; INITIAL DEVICE

0450T INSERTION OF AQUEOUS DRAINAGE DEVICE, WITHOUT EXTRAOCULAR RESERVOIR, INTERNAL APPROACH, INTO THE SUBCONJUNCTIVAL SPACE; EACH ADDITIONAL DEVICE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph: N/A

Group 1 Codes:

ICD-10 Codes Description

H40.10X1 Unspecified open-angle glaucoma, mild stage
H40.10X2 Unspecified open-angle glaucoma, moderate stage
H40.10X3 Unspecified open-angle glaucoma, severe stage
H40.10X4 Unspecified open-angle glaucoma, indeterminate stage
H40.1111 Primary open-angle glaucoma, right eye, mild stage
H40.1112 Primary open-angle glaucoma, right eye, moderate stage
H40.1113 Primary open-angle glaucoma, right eye, severe stage
H40.1114 Primary open-angle glaucoma, right eye, indeterminate stage
H40.1121 Primary open-angle glaucoma, left eye, mild stage
H40.1122 Primary open-angle glaucoma, left eye, moderate stage
H40.1123 Primary open-angle glaucoma, left eye, severe stage
H40.1124 Primary open-angle glaucoma, left eye, indeterminate stage
H40.1131 Primary open-angle glaucoma, bilateral, mild stage
H40.1132 Primary open-angle glaucoma, bilateral, moderate stage
H40.1133 Primary open-angle glaucoma, bilateral, severe stage
H40.1134 Primary open-angle glaucoma, bilateral, indeterminate stage
H40.1211 Low-tension glaucoma, right eye, mild stage
H40.1212 Low-tension glaucoma, right eye, moderate stage
H40.1213 Low-tension glaucoma, right eye, severe stage
H40.1214 Low-tension glaucoma, right eye, indeterminate stage
H40.1221 Low-tension glaucoma, left eye, mild stage
H40.1222 Low-tension glaucoma, left eye, moderate stage
H40.1223 Low-tension glaucoma, left eye, severe stage
H40.1224 Low-tension glaucoma, left eye, indeterminate stage
H40.1231 Low-tension glaucoma, bilateral, mild stage
H40.1232 Low-tension glaucoma, bilateral, moderate stage
H40.1233 Low-tension glaucoma, bilateral, severe stage
H40.1234 Low-tension glaucoma, bilateral, indeterminate stage
H40.1311 Pigmentary glaucoma, right eye, mild stage
H40.1312 Pigmentary glaucoma, right eye, moderate stage
H40.1313 Pigmentary glaucoma, right eye, severe stage
H40.1314 Pigmentary glaucoma, right eye, indeterminate stage
H40.1321 Pigmentary glaucoma, left eye, mild stage
H40.1322 Pigmentary glaucoma, left eye, moderate stage

Printed on 12/12/2017. Page 8 of 11
ICD-10 Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H40.1323</td>
<td>Pigmentary glaucoma, left eye, severe stage</td>
</tr>
<tr>
<td>H40.1324</td>
<td>Pigmentary glaucoma, left eye, indeterminate stage</td>
</tr>
<tr>
<td>H40.1331</td>
<td>Pigmentary glaucoma, bilateral, mild stage</td>
</tr>
<tr>
<td>H40.1332</td>
<td>Pigmentary glaucoma, bilateral, moderate stage</td>
</tr>
<tr>
<td>H40.1333</td>
<td>Pigmentary glaucoma, bilateral, severe stage</td>
</tr>
<tr>
<td>H40.1334</td>
<td>Pigmentary glaucoma, bilateral, indeterminate stage</td>
</tr>
<tr>
<td>H40.1411</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage</td>
</tr>
<tr>
<td>H40.1412</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage</td>
</tr>
<tr>
<td>H40.1413</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage</td>
</tr>
<tr>
<td>H40.1414</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage</td>
</tr>
<tr>
<td>H40.1421</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage</td>
</tr>
<tr>
<td>H40.1422</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage</td>
</tr>
<tr>
<td>H40.1423</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage</td>
</tr>
<tr>
<td>H40.1424</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage</td>
</tr>
<tr>
<td>H40.1431</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage</td>
</tr>
<tr>
<td>H40.1432</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage</td>
</tr>
<tr>
<td>H40.1433</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage</td>
</tr>
<tr>
<td>H40.1434</td>
<td>Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage</td>
</tr>
</tbody>
</table>

ICD-10 Codes that DO NOT Support Medical Necessity

**Group 1 Paragraph:**

Any ICD-10-CM code not listed in Group 1 "ICD-10 Codes that Support Medical Necessity" section

**Group 1 Codes:** N/A

ICD-10 Additional Information [Back to Top]

**General Information**

**Associated Information**

**Documentation Requirements:**
The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures. The medical record and/or test results documenting medical necessity should be maintained and made available on request.

Micro-Invasive Glaucoma Surgery (MIGS) must be performed in conjunction with cataract surgery on the same date of service and documented in the medical record.

**Sources of Information**

N/A

**Bibliography**


Printed on 12/12/2017. Page 9 of 11


